Hence, clinical trial results have been recently summarized by Drilon et al. (2024) who reported (TRIDENT-1 phase 1–2 trial) that the median PFS for ROS1-fusion positive NSCLC patients was 35.7 months (95% CI 27.4-unable to estimate) [16]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.